Table of Contents
CHAPTER 1 INTRODUCTION
- 1.1 What is this report about?
- 1.2 Who is the target reader?
- 1.3 How to use this report
- 1.4 Definitions
CHAPTER 2 GROUP OF EIGHT (G8) OTC
- PHARMACEUTICALS INDUSTRY OUTLOOK
CHAPTER 3 OTC PHARMACEUTICALS IN CANADA
- 3.1 Market Overview
- 3.2 Market Value
- 3.3 Market Segmentation I
- 3.4 Market Segmentation II
- 3.5 Market Share
- 3.6 Five Forces Analysis
- 3.7 Leading Companies
- 3.8 Distribution
- 3.9 Market Forecasts
- 3.10 Macroeconomic Indicators
CHAPTER 4 OTC PHARMACEUTICALS IN FRANCE
- 4.1 Market Overview
- 4.2 Market Value
- 4.3 Market Segmentation I
- 4.4 Market Segmentation II
- 4.5 Market Share
- 4.6 Five Forces Analysis
- 4.7 Leading Companies
- 4.8 Distribution
- 4.9 Market Forecasts
- 4.10 Macroeconomic Indicators
CHAPTER 5 OTC PHARMACEUTICALS IN GERMANY
- 5.1 Market Overview
- 5.2 Market Value
- 5.3 Market Segmentation I
- 5.4 Market Segmentation II
- 5.5 Market Share
- 5.6 Five Forces Analysis
- 5.7 Leading Companies
- 5.8 Distribution
- 5.9 Market Forecasts
- 5.10 Macroeconomic Indicators
CHAPTER 6 OTC PHARMACEUTICALS IN ITALY
- 6.1 Market Overview
- 6.2 Market Value
- 6.3 Market Segmentation I
- 6.4 Market Segmentation II
- 6.5 Market Share
- 6.6 Five Forces Analysis
- 6.7 Leading Companies
- 6.8 Distribution
- 6.9 Market Forecasts
- 6.10 Macroeconomic Indicators
CHAPTER 7 OTC PHARMACEUTICALS IN JAPAN
- 7.1 Market Overview
- 7.2 Market Value
- 7.3 Market Segmentation I
- 7.4 Market Segmentation II
- 7.5 Market Share
- 7.6 Five Forces Analysis
- 7.7 Leading Companies
- 7.8 Distribution
- 7.9 Market Forecasts
- 7.10 Macroeconomic Indicators
CHAPTER 8 OTC PHARMACEUTICALS IN RUSSIA
- 8.1 Market Overview
- 8.2 Market Value
- 8.3 Market Segmentation I
- 8.4 Market Segmentation II
- 8.5 Market Share
- 8.6 Five Forces Analysis
- 8.7 Leading Companies
- 8.8 Distribution
- 8.9 Market Forecasts
- 8.10 Macroeconomic Indicators
CHAPTER 9 OTC PHARMACEUTICALS IN THE UNITED
- KINGDOM
- 9.1 Market Overview
- 9.2 Market Value
- 9.3 Market Segmentation I
- 9.4 Market Segmentation II
- 9.5 Market Share
- 9.6 Five Forces Analysis
- 9.7 Leading Companies
- 9.8 Distribution
- 9.9 Market Forecasts
- 9.10 Macroeconomic Indicators
CHAPTER 10 OTC PHARMACEUTICALS IN THE UNITED
- STATES
- 10.1 Market Overview
- 10.2 Market Value
- 10.3 Market Segmentation I
- 10.4 Market Segmentation II
- 10.5 Market Share
- 10.6 Five Forces Analysis
- 10.7 Leading Companies
- 10.8 Distribution
- 10.9 Market Forecasts
- 10.10 Macroeconomic Indicators
CHAPTER 11 APPENDIX
- 11.1 Data Research Methodology
LIST OF TABLES
- Table 1: G8 OTC Pharmaceuticals industry, revenue ($ bn), 2004 - 2013
24
- Table 2: G8 OTC Pharmaceuticals industry, revenue by country ($ bn) 2004 -
2008(e) 27
- Table 3: G8 OTC Pharmaceuticals industry forecast, revenue by country ($
bn) 2008 - 2013 29
- Table 4: Canada OTC Pharmaceuticals Market Value: $ billion, 2004- 2008(e)
31
- Table 5: Canada OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 32
- Table 6: Canada OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 33
- Table 7: Canada OTC Pharmaceuticals Market Share: % Share, by Value, 2007
34
- Table 8: Key Facts: Pfizer Inc 41
- Table 9: Key Financials: Pfizer Inc 43
- Table 10: Key Facts: GlaxoSmithKline Plc 44
- Table 11: Key Financials: GlaxoSmithKline Plc 47
- Table 12: Key Facts: Jamieson Laboratories 48
- Table 13: Canada OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 49
- Table 14: Canada OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 50
- Table 15: Canada Size of Population (million) , 2004- 2008(e) 51
- Table 16: Canada GDP (Constant 2000 Prices, $ billion), 2004- 2008(e)
51
- Table 17: Canada Inflation, 2004- 2008(e) 52
- Table 18: Canada Exchange Rate, 2004- 2008(e) 52
- Table 19: France OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
54
- Table 20: France OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 55
- Table 21: France OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 56
- Table 22: France OTC Pharmaceuticals Market Share: % Share, by Value, 2007
57
- Table 23: Key Facts: Procter & Gamble Company, The 64
- Table 24: Key Financials: Procter & Gamble Company, The 67
- Table 25: Key Facts: Sanofi-Aventis SA 68
- Table 26: Key Financials: Sanofi-Aventis SA 69
- Table 27: Key Facts: Pfizer Inc 70
- Table 28: Key Financials: Pfizer Inc 72
- Table 29: France OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 73
- Table 30: France OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 74
- Table 31: France Size of Population (million) , 2004- 2008(e) 75
- Table 32: France GDP (Constant 2000 Prices, $ billion), 2004- 2008(e)
75
- Table 33: France Inflation, 2004- 2008(e) 76
- Table 34: France Exchange Rate, 2004- 2008(e) 76
- Table 35: Germany OTC Pharmaceuticals Market Value: $ billion, 2004-
2008(e) 78
- Table 36: Germany OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 79
- Table 37: Germany OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 80
- Table 38: Germany OTC Pharmaceuticals Market Share: % Share, by Value,
2007 81
- Table 39: Key Facts: Bayer AG 88
- Table 40: Key Financials: Bayer AG 91
- Table 41: Key Facts: Pfizer Inc 92
- Table 42: Key Financials: Pfizer Inc 94
- Table 43: Key Facts: GlaxoSmithKline Plc 95
- Table 44: Key Financials: GlaxoSmithKline Plc 98
- Table 45: Germany OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 99
- Table 46: Germany OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013100
- Table 47: Germany Size of Population (million) , 2004- 2008(e) 101
- Table 48: Germany GDP (Constant 2000 Prices, $ billion), 2004- 2008(e)
101
- Table 49: Germany Inflation, 2004- 2008(e) 102
- Table 50: Germany Exchange Rate, 2004- 2008(e) 102
- Table 51: Italy OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
104
- Table 52: Italy OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e)
- Table 53: Italy OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e)
- Table 54: Italy OTC Pharmaceuticals Market Share: % Share, by Value, 2007
107
- Table 55: Key Facts: Bayer AG 114
- Table 56: Key Financials: Bayer AG 117
- Table 57: Key Facts: GlaxoSmithKline Plc 118
- Table 58: Key Financials: GlaxoSmithKline Plc 121
- Table 59: Key Facts: Novartis AG 122
- Table 60: Key Financials: Novartis AG 124
- Table 61: Italy OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 125
- Table 62: Italy OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 126
- Table 63: Italy Size of Population (million) , 2004- 2008(e) 127
- Table 64: Italy GDP (Constant 2000 Prices, $ billion), 2004- 2008(e)
127
- Table 65: Italy Inflation, 2004- 2008(e) 128
- Table 66: Italy Exchange Rate, 2004- 2008(e) 128
- Table 67: Japan OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
130
- Table 68: Japan OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 131
- Table 69: Japan OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 132
- Table 70: Japan OTC Pharmaceuticals Market Share: % Share, by Value, 2007
133
- Table 71: Key Facts: Pfizer Inc 140
- Table 72: Key Financials: Pfizer Inc 142
- Table 73: Key Facts: Novartis AG 143
- Table 74: Key Financials: Novartis AG 145
- Table 75: Key Facts: Wyeth 146
- Table 76: Key Financials: Wyeth 148
- Table 77: Japan OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 149
- Table 78: Japan OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 150
- Table 79: Japan Size of Population (million) , 2004-2008(e) 151
- Table 80: Japan GDP (Constant 2000 Prices, $ billion), 2004-2008(e)
151
- Table 81: Japan Inflation, 2004-2008(e) 152
- Table 82: Japan Exchange Rate, 2004-2008(e) 152
- Table 83: Russia OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
154
- Table 84: Russia OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 155
- Table 85: Russia OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 156
- Table 86: Russia OTC Pharmaceuticals Market Share: % Share, by Value, 2007
157
- Table 87: Key Facts: Ranbaxy Laboratories Limited 164
- Table 88: Key Financials: Ranbaxy Laboratories Limited 165
- Table 89: Key Facts: Zentiva NV 166
- Table 90: Key Financials: Zentiva NV 167
- Table 91: Key Facts: KRKA 168
- Table 92: Russia OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 170
- Table 93: Russia OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 171
- Table 94: Russia Size of Population (million) , 2004-2008(e) 172
- Table 95: Russia GDP (Constant 2000 Prices, $ billion), 2004-2008(e)
172
- Table 96: Russia Inflation, 2004-2008(e) 173
- Table 97: Russia Exchange Rate, 2004-2008(e) 173
- Table 98: United Kingdom OTC Pharmaceuticals Market Value: $ billion,
2004- 2008(e)
- Table 99: United Kingdom OTC Pharmaceuticals Market Segmentation I: %
Share, by Value, 2008(e) 176
- Table 100: United Kingdom OTC Pharmaceuticals Market Segmentation II: %
Share, by Value, 2008(e) 177
- Table 101: United Kingdom OTC Pharmaceuticals Market Share: % Share, by
Value, 2007
- Table 102: Key Facts: GlaxoSmithKline Plc 185
- Table 103: Key Financials: GlaxoSmithKline Plc 188
- Table 104: Key Facts: Pfizer Inc 189
- Table 105: Key Financials: Pfizer Inc 191
- Table 106: Key Facts: Reckitt Benckiser PLC 192
- Table 107: Key Financials: Reckitt Benckiser PLC 194
- Table 108: United Kingdom OTC Pharmaceuticals Distribution: % Share, by
Value, 2008(e)
- Table 109: United Kingdom OTC Pharmaceuticals Market Value Forecast: $
billion, 2008- 2013 196
- Table 110: United Kingdom Size of Population (million) , 2004-2008(e)
197
- Table 111: United Kingdom GDP (Constant 2000 Prices, $ billion),
2004-2008(e) 197
- Table 112: United Kingdom Inflation, 2004-2008(e) 198
- Table 113: United Kingdom Exchange Rate, 2004-2008(e) 198
- Table 114: United States OTC Pharmaceuticals Market Value: $ billion,
2004-2008(e) 200
- Table 115: United States OTC Pharmaceuticals Market Segmentation I: %
Share, by Value, 2008(e) 201
- Table 116: United States OTC Pharmaceuticals Market Segmentation II: %
Share, by Value, 2008(e) 202
- Table 117: United States OTC Pharmaceuticals Market Share: % Share, by
Value, 2007
- Table 118: Key Facts: Pfizer Inc 211
- Table 119: Key Financials: Pfizer Inc 213
- Table 120: Key Facts: GlaxoSmithKline Plc 214
- Table 121: Key Financials: GlaxoSmithKline Plc 217
- Table 122: Key Facts: Wyeth 218
- Table 123: Key Financials: Wyeth 220
- Table 124: United States OTC Pharmaceuticals Distribution: % Share, by
Value, 2008(e)
- Table 125: United States OTC Pharmaceuticals Market Value Forecast: $
billion, 2008-2013 222
- Table 126: United States Size of Population (million) , 2004- 2008(e)
223
- Table 127: United States GDP (Constant 2000 Prices, $ billion), 2004-
2008(e) 223
- Table 128: United States Inflation, 2004- 2008(e) 223
LIST OF FIGURES
- Figure 1: G8 OTC Pharmaceuticals industry, revenue ($ bn) 2004 - 2013
24
- Figure 2: G8 OTC Pharmaceuticals industry, revenue by country (%) 2008e
25
- Figure 3: G8 OTC Pharmaceuticals industry, revenue by country ($ bn) 2004
- 2008(e) 26
- Figure 4: G8 OTC Pharmaceuticals industry forecast, revenue by country ($
bn) 2008 - 2013 28
- Figure 5: Canada OTC Pharmaceuticals Market Value: $ billion, 2004-
2008(e) 31
- Figure 6: Canada OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 32
- Figure 7: Canada OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 33
- Figure 8: Canada OTC Pharmaceuticals Market Share: % Share, by Value, 2007
34
- Figure 9: Forces Driving Competition in the OTC Pharmaceuticals Market in
Canada 35
- Figure 10: Drivers of Buyer Power in the OTC Pharmaceuticals Market in
Canada 36
- Figure 11: Drivers of Supplier Power in the OTC Pharmaceuticals Market in
Canada 37
- Figure 12: Factors Influencing the Likelihood of New Entrants in the OTC
Pharmaceuticals Market in Canada 38
- Figure 13: Factors Influencing the Threat of Substitutes in the OTC
Pharmaceuticals Market in Canada 39
- Figure 14: Drivers of Degree of Rivalry in the OTC Pharmaceuticals Market
in Canada 40
- Figure 15: Revenues & Profitability: Pfizer Inc 43
- Figure 16: Revenues & Profitability: GlaxoSmithKline Plc 47
- Figure 17: Canada OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 49
- Figure 18: Canada OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 50
- Figure 19: France OTC Pharmaceuticals Market Value: $ billion,
2004-2008(e) 54
- Figure 20: France OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 55
- Figure 21: France OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 56
- Figure 22: France OTC Pharmaceuticals Market Share: % Share, by Value,
2007 57
- Figure 23: Forces Driving Competition in the OTC Pharmaceuticals Market in
France 58
- Figure 24: Drivers of Buyer Power in the OTC Pharmaceuticals Market in
France 59
- Figure 25: Drivers of Supplier Power in the OTC Pharmaceuticals Market in
France 60
- Figure 26: Factors Influencing the Likelihood of New Entrants in the OTC
Pharmaceuticals Market in France 61
- Figure 27: Factors Influencing the Threat of Substitutes in the OTC
Pharmaceuticals Market in France 62
- Figure 28: Drivers of Degree of Rivalry in the OTC Pharmaceuticals Market
in France 63
- Figure 29: Revenues & Profitability: Procter & Gamble Company, The 67
- Figure 30: Revenues & Profitability: Sanofi-Aventis SA 69
- Figure 31: Revenues & Profitability: Pfizer Inc 72
- Figure 32: France OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 73
- Figure 33: France OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 74
- Figure 34: Germany OTC Pharmaceuticals Market Value: $ billion, 2004-
2008(e) 78
- Figure 35: Germany OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 79
- Figure 36: Germany OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 80
- Figure 37: Germany OTC Pharmaceuticals Market Share: % Share, by Value,
2007 81
- Figure 38: Forces Driving Competition in the OTC Pharmaceuticals Market in
Germany 82
- Figure 39: Drivers of Buyer Power in the OTC Pharmaceuticals Market in
Germany 83
- Figure 40: Drivers of Supplier Power in the OTC Pharmaceuticals Market in
Germany 84
- Figure 41: Factors Influencing the Likelihood of New Entrants in the OTC
Pharmaceuticals Market in Germany 85
- Figure 42: Factors Influencing the Threat of Substitutes in the OTC
Pharmaceuticals Market in Germany 86
- Figure 43: Drivers of Degree of Rivalry in the OTC Pharmaceuticals Market
in Germany 87
- Figure 44: Revenues & Profitability: Bayer AG 91
- Figure 45: Revenues & Profitability: Pfizer Inc 94
- Figure 46: Revenues & Profitability: GlaxoSmithKline Plc 98
- Figure 47: Germany OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 99
- Figure 48: Germany OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013100
- Figure 49: Italy OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
104
- Figure 50: Italy OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e)
- Figure 51: Italy OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e)
- Figure 52: Italy OTC Pharmaceuticals Market Share: % Share, by Value, 2007
107
- Figure 53: Forces Driving Competition in the OTC Pharmaceuticals Market in
Italy 108
- Figure 54: Drivers of Buyer Power in the OTC Pharmaceuticals Market in
Italy 109
- Figure 55: Drivers of Supplier Power in the OTC Pharmaceuticals Market in
Italy 110
- Figure 56: Factors Influencing the Likelihood of New Entrants in the OTC
Pharmaceuticals Market in Italy 111
- Figure 57: Factors Influencing the Threat of Substitutes in the OTC
Pharmaceuticals Market in Italy 112
- Figure 58: Drivers of Degree of Rivalry in the OTC Pharmaceuticals Market
in Italy 113
- Figure 59: Revenues & Profitability: Bayer AG 117
|
Related Report
|
View Cart
